The WuXi PharmaTech-backed genomic medicine developer floated below its range, after raising $125m in venture capital.

Sanofi-backed Selecta Biosciences had raised $117m prior to the offering, and will use the proceeds to advance its gout treatment through clinical trials.

The business communication technology provider, which had raised $240m from investors including Amazon and Salesforce, will float above its range.

The Duowan Entertainment-backed English language learning platform has raised $45.6m in a US initial public offering and will secure another $20m through a private placement.

Naver-owned messaging platform Line is set to sell 13 million shares in Japan and 22 million shares in the US priced at $26.30 each for a dual listing.

Internet Thailand intends to keep its 25% stake in the Thailand-based back-office services provider.

The initial public offering on Aim will provide an exit to shareholders including Novartis, which gave Mereo access to three of its clinical stage therapies last year.

The RFID technology developer, backed by investors such as UPS and Intel, has filed for a $60m IPO after previously withdrawing a $100m offering in 2012.

Santen-backed Clearside Biomedical, which had raised some $48m in funding, is offering 7.2 million shares on Nasdaq priced at $7 each.

The personalised healthcare subsidiary of NantWorks, backed by Celgene, Blackberry and Allscripts, has priced its initial public offering at $14 a share.